Matrix Healthcare Solutions Adds MIA (IMP) to Portfolio of Licenses
Matrix Healthcare Solutions (MHS) has further complimented its expansive licensed capabilities with the addition of a Manufacturers Import Authorisation (MIA) for Investigational Medicinal Products (IMP). The stringent controls and high standards required for IMP management in clinical trials have a direct impact on product registration with regulatory and competent authorities around the world. The MIA (IMP) allows Matrix Healthcare Solutions to better serve its increasing global base of customers.
Matrix Healthcare Solutions Granted Direct Access to Pfizer Medicines
Matrix Healthcare Solutions is delighted to announce we have been granted direct access to medicines from Pfizer limited, for the purposes of supplying third party clinical trials, this covers access to the full UK / EU licenced portfolio of 453 lines. The Pfizer portfolio includes a number of oncology, antibacterial, and biologic medicines.
Biosimilar Clinical Trials Today & Tomorrow
Biological products, also known as biologics, have formed a cornerstone of modern healthcare for decades. Blood transfusions, gene therapy, monoclonal antibody treatment, vaccinations, and many more key clinical processes rely on goods derived from living organisms rather than chemical synthesis. Unfortunately, the development and manufacture of biologics can be extremely expensive. A common topic of debate by key opinion leaders in recent years has been the emergence of biosimilars and how to accelerate clinical trials in biosimilar development programs. What are Biosimilars? Biosimilars aim to reduce the costs associated with biologically-derived treatments without inhibiting the clinical significance of the innovator product. The goal is to identify
National Accelerated Licensing Routes to Improve Clinical Trial Supply
The Medicines and Healthcare Products Regulatory Agency (MHRA) has released its 2020-21 business plan, outlining its primary goals for the coming year. Driven by the need to develop new regulatory models and improving patient access to cutting-edge drugs and medical devices, the plan concerns various aspects of the British life sciences industry, including the efficacy and efficiency of clinical trial supplies. In the executive summary, the plan sets out the primary aim of “driving forward a substantial strategic and cultural change through 2020-21”. Though the document discusses a range of granular challenges in healthcare and medicine, two of the biggest issues covered are the
Matrix Healthcare Solutions Expands with a Manufacturer’s “Specials” License
Matrix Healthcare Solutions further expands licensed capabilities with the addition of Manufacturer’s “Specials” (MS) license.
Clinical Trial News: Drug Combo Tested in Severe COVID-19
Various news outlets around the world have reported on apparent clinical trials testing the efficacy of anti-HIV (human immunodeficiency viruses) medication in combatting COVID-19.
Clinical Trial Supply: What are Adjuvants?
At Matrix Healthcare Solutions (MHS), we specialize in providing bespoke supply strategies and clinical trial services at every step in the clinical trial lifespan.
Matrix Healthcare Solutions appoints Zac Gilles as Director, Clinical Supplies
Zac has focused his career in the pharmaceutical industry, sourcing comparative medicines for use in a wide category of Clinical Trials.
Matrix Healthcare Solutions Expands Licensed Capabilities
Alongside several key brick-and-mortar expansions, Matrix Healthcare Solutions (MHS) has also developed a wider base of licensed capabilities, allowing us to support a broader range of customer requirements.
Will Plumb Joins Matrix Healthcare Solutions as Director, Clinical Supplies
Matrix Healthcare Solutions are delighted to welcome Will Plumb into the team as Director, Clinical Supplies.